Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown DHA + Regorafenib kidney cancer not applicable detail...
PTEN inact mut LY3023414 kidney cancer sensitive detail...
VHL V155fs Sunitinib + Trametinib kidney cancer predicted - sensitive detail...
Unknown unknown OPB-111077 kidney cancer not applicable detail...
Unknown unknown CVX-241 kidney cancer no benefit detail...
Unknown unknown CVX-060 + Sunitinib kidney cancer not applicable detail...
Unknown unknown ISTH0047 kidney cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00184015 Bevacizumab Bortezomib Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Active, not recruiting
NCT00375674 Sunitinib A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Completed
NCT00923130 Phase II Bevacizumab + Ixabepilone Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer Completed
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed
NCT01184326 Phase I everolimus + pazopanib An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer Completed
NCT01217931 Phase II Everolimus Pazopanib Bevacizumab Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy Active, not recruiting
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01480154 Phase I MK2206 + hydroxychloroquine Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting
NCT01497444 Phase Ib/II Evofosfamide + Sorafenib Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery Active, not recruiting
NCT01727089 Phase II Bevacizumab Bevacizumab + Carotuximab Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer Completed
NCT02077933 Phase I BYL719 + Everolimus BYL719 + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Active, not recruiting
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02460224 Phase Ib/II LAG525 PDR001 Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02504892 Phase II Everolimus Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer Terminated
NCT02643303 Phase Ib/II MEDI4736 + poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02655822 Phase I Atezolizumab CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02899078 Phase Ib/II Ibrutinib + Nivolumab Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Recruiting
NCT02964078 Phase II Aldesleukin + Pembrolizumab Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer Active, not recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting